<DOC>
	<DOC>NCT02209155</DOC>
	<brief_summary>This is a double-blinded, randomized, parallel, placebo-controlled phase 2 study to evaluate the safety and efficacy of R-verapamil in the prophylaxis of episodic cluster headache.</brief_summary>
	<brief_title>R-Verapamil for the Prophylaxis of Episodic Cluster Headache</brief_title>
	<detailed_description>Approximately 30 subjects (about 15 per treatment group),will be enrolled and randomized to receive either R-verapamil or placebo for 2 weeks. The study will consist of a 1-week run-in period and a 2-week treatment period (R-verapamil or placebo). The total duration of the study for each treatment group is 3 weeks.</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Healthy man or woman between the ages of 18 and 65 In good health as determined by medical history and medical examination Has a diagnosis of episodic cluster headache as defined by the International Classification of Headache Disorders (2nd edition) Has a lifetime prevalence of at least 2 prior cluster bouts Subjects must experience at least 7 attacks/week during the runin baseline period Subjects must have a typical cluster period lasting at least 1 month. Subjects must be present in active cluster period and the expected remaining duration of the cluster cycle must be at least 3 weeks from Baseline Day 1 visit Able to differentiate other headache types from cluster headaches Is using or agrees to use a medically acceptable form of contraception(female of childbearing potential) Negative urine pregnancy test prior to study entry(female of childbearing potential) Concomitant medication that, in the opinion of the investigator and the patient's general practitioner(GP), do not pose an unacceptable risk based upon the prescribing information for verapamil Able to understand and comply with all study requirements Written informed consent Women who are pregnant or lactating Subjects who, in the investigators opinion, have a history or have evidence of a medical or psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability Use of any drug or having any medical condition which might interact adversely with, or interfere with the action of, the study medication The concomitant use of beta blockers The consumption of grapefruit juice Allergic to or has shown hypersensitivity to verapamil or agents similar to verapamil Abuses opioids or has a history of significant drug or alcohol abuse within the past year as determined by investigator Has participated in an investigational drug trial in the 30 days prior to the screening visit Has liver or kidney disease Has a cardiopathology contraindicating verapamil administration Subjects with previous adynamic ileus. Subjects with chronic cluster headache Use of antipsychotic, antidepressants, lithium or other prophylactic treatment less than one month prior to inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>